Publication date: Apr 16, 2025
This real-world study also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients of Novavaxs vaccine. Local reactogenicity events also showed an absolute difference of 12. 5% fewer in Novavax recipients versus Pfizer-BioNTech recipients. The SHIELD study found health care workers who received the Novavax vaccine reported significantly fewer reactogenicity events than Pfizer-BioNTech recipients. The results were presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025.
| Concepts | Keywords |
|---|---|
| Microbiology | Biontech |
| Severe | Compared |
| Utah | Covid |
| Vaccines | Daily |
| Fewer | |
| Lower | |
| Novavax | |
| Novavaxs | |
| Pfizer | |
| Reactogenicity | |
| Recipients | |
| Shield | |
| Showed | |
| Symptoms | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | symptom |
| disease | MESH | Infectious Diseases |
Original Article
(Visited 2 times, 1 visits today)